Amydis_Logo_Horiz_RGB@2x.png
Amydis Announces Successful Completion of Pre-IND Meeting with the FDA for the Development of a First-in-Class Retinal Tracer for the Diagnosis of Alpha-synucleinopathies
April 26, 2021 07:00 ET | Amydis, Inc.
SAN DIEGO, April 26, 2021 (GLOBE NEWSWIRE) -- Amydis Inc., a leading ocular tracer biotechnology company with a broad portfolio of diagnostic candidates for detection of neurodegenerative diseases...
Logo.png
Multiple System Atrophy Pipeline Expected to Offer Myriad of Novel Therapies in the Next Decade
January 13, 2021 18:30 ET | DelveInsight Business Research LLP
Los Angeles, USA, Jan. 13, 2021 (GLOBE NEWSWIRE) -- Multiple System Atrophy Pipeline Expected to Offer Myriad of Novel Therapies in the Next Decade Multiple System Atrophy Clinical Trial Analysis...
Amydis_Logo_Horiz_RGB@2x.png
Amydis Awarded Michael J. Fox Foundation Grant to Accelerate Development of an Alpha-Synuclein Retinal Tracer to Diagnose Parkinson’s Disease Through the Eye
August 11, 2020 07:00 ET | Amydis, Inc.
SAN DIEGO, Aug. 11, 2020 (GLOBE NEWSWIRE) -- Amydis, Inc., a biotechnology company developing a new class of diagnostics to enable the early detection of neurological diseases through the retina,...